Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis

被引：6
作者：
Ling Q. [1 ,2 ]
Huang S.-T. [1 ,2 ]
Yu T.-H. [1 ,2 ]
Liu H.-L. [3 ]
Zhao L.-Y. [1 ,2 ]
Chen X.-L. [1 ,2 ]
Liu K. [1 ,2 ]
Chen X.-Z. [1 ,2 ]
Yang K. [1 ,2 ]
Hu J.-K. [1 ,2 ]
Zhang W.-H. [1 ,2 ]
机构：
[1] Department of General Surgery, West China Hospital, Sichuan University, Sichuan Province, Chengdu
[2] Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu
[3] West China School of Medicine, Sichuan University, Chengdu
来源：
World Journal of Surgical Oncology | / 21卷 / 1期
关键词：
Advanced gastric cancer; Disease-free survival; Neoadjuvant chemotherapy; Overall survival; Time to surgery;
D O I：
10.1186/s12957-023-03251-y
中图分类号：
学科分类号：
摘要：
Background: Following neoadjuvant chemotherapy, surgical resection is one of the most preferred treatment options for locally advanced gastric cancer patients. However, the optimal time interval between chemotherapy and surgery is unclear. This review aimed to identify the optimal time interval between neoadjuvant chemotherapy and surgery for advanced gastric cancer. Methods: Beginning on November 12, 2022, we searched the PubMed, Cochrane Library, Web of Science databases, and Embase.com databases for relevant English-language research. Two authors independently screened the studies, assessed their quality, extracted the data, and analyzed the results. The primary goal was to investigate the relationship between the time interval to surgery (TTS) and long-term survival outcomes for patients. This study has been registered with PROSPERO (CRD42022365196). Results: After an initial search of 4880 articles, the meta-analysis review ultimately included only five retrospective studies. Ultimately, this meta-analysis included 1171 patients, of which 411 patients had TTS of < 4 weeks, 507 patients had TTS of 4–6 weeks, and 253 patients had TTS of > 6 weeks. In survival analysis, patients with TTS of > 6 weeks had poorer overall survival outcomes than patients with TTS of 4–6 weeks (HR = 1.34, 95% CI: 1.03–1.75, P = 0.03). No significant differences were found in terms of disease-free survival the groups. Conclusion: Based on the current clinical evidence, patients with locally advanced gastric cancer may benefit better with a TTS of 4–6 weeks; however, this option still needs additional study. © 2023, The Author(s).
引用
收藏
相关论文
共 38 条
[1]  
Sung H., Et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 3, pp. 209-249, (2021)
[2]  
Sexton R.E., Et al., Gastric cancer: a comprehensive review of current and future treatment strategies, Cancer Metastasis Rev, 39, 4, pp. 1179-1203, (2020)
[3]  
Cunningham S.C., Et al., Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution, J Gastrointest Surg, 9, 5, pp. 718-725, (2005)
[4]  
Chen W., Et al., Annual report on status of cancer in China, 2011, Chin J Cancer Res, 27, 1, pp. 2-12, (2015)
[5]  
Zheng R., Et al., Cancer incidence and mortality in China, 2016, JNCC, 2, 1, pp. 1-9, (2022)
[6]  
Cunningham D., Et al., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 355, 1, pp. 11-20, (2006)
[7]  
Coccolini F., Et al., Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials, Int J Surg, 51, pp. 120-127, (2018)
[8]  
van Hagen P., Et al., Preoperative chemoradiotherapy for esophageal or junctional cancer, N Engl J Med, 366, 22, pp. 2074-2084, (2012)
[9]  
Ajani J.A., Et al., Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome, J Clin Oncol, 23, 6, pp. 1237-1244, (2005)
[10]  
Lowy A.M., Et al., A pilot study of preoperative chemoradiotherapy for resectable gastric cancer, Ann Surg Oncol, 8, 6, pp. 519-524, (2001)
1234